良性前列腺增生、下尿路症状和前列腺癌经常同时出现。它们对尿液功能的影响是关于前列腺癌治疗选择的重要考虑。虽然前列腺体积（PV）和尿液症状通常用于治疗选择决策，但它们与治疗后尿液功能的关联还不清楚。我们评估了局部前列腺癌男性患者中PV和基线尿液功能与治疗选择以及治疗后尿液功能之间的关联。我们从CEASAR识别了1647名患者，CEASAR是一项多中心人群基础前瞻性队列研究，研究男性患有局部前列腺癌。主要结果是治疗选择和健康相关生命质量（HRQOL），通过26项扩展前列腺指数组合（EPIC-26）在预定时间间隔内进行评估，最长时间为5年。进行多变量分析，控制人口特征和临床病理特征。中位基线PV为36毫升（IQR 27-48），基线尿液刺激性/梗阻性领域得分为87（IQR 75-100）。在PV和治疗选择或治疗后尿液功能之间没有发现临床上有意义的关联。在基础尿液功能较差的患者中，放射治疗或手术治疗与尿液功能的统计和临床显着改善有关，在6个月内能持续5年（放射治疗改善得分为20.4点，手术改善得分为24.5点）。在接受局部前列腺癌治疗的男性中，PV未被发现与治疗方式或治疗后尿液刺激性/梗阻性功能相关。基础尿液刺激性/梗阻性功能较差的男性在接受手术或放射治疗后有所改善。© 2022。作者（s），在Springer Nature Limited的独家许可下。

Benign prostatic hyperplasia, lower urinary tract symptoms, and prostate cancer often co-occur. Their effect on urinary function is an important consideration regarding prostate cancer treatment choices. While prostate volume (PV) and urinary symptoms are commonly used in treatment choice decision making, their association with post-treatment urinary function is unknown. We evaluated the associations between PV and baseline urinary function with treatment choice and post-treatment urinary function among men with localized prostate cancer.We identified 1647 patients from CEASAR, a multicenter population-based, prospective cohort study of men with localized prostate cancer, for analysis. Primary outcomes were treatment choice and health-related quality of life (HRQOL) assessed by the 26-item Expanded Prostate Index Composite (EPIC-26) at pre-specified intervals up to 5 years. Multivariable analysis was performed, controlling for demographic and clinicopathologic features.Median baseline PV was 36 mL (IQR 27-48), and baseline urinary irritative/obstructive domain score was 87 (IQR 75-100). There was no observed clinically meaningful association between PV and treatment choice or post-treatment urinary function. Among patients with poor baseline urinary function, treatment with radiation or surgery was associated with statistically and clinically significant improvement in urinary function at 6 months which was durable through 5 years (improvement from baseline at 5 years: radiation 20.4 points, surgery 24.5 points).PV was not found to be associated with treatment modality or post-treatment urinary irritative/obstructive function among men treated for localized prostate cancer. Men with poor baseline urinary irritative/obstructive function improve after treatment with surgery or radiation therapy.© 2022. The Author(s), under exclusive licence to Springer Nature Limited.